Effect of early cyclosporine levels on kidney allograft rejection

Clinical Transplantation

Volumn 11, Issue 6, 1997, Pages 552-557

  Johnson, E M ^a   Canafax, D M ^a   Gillingham, K J ^a   Humar, A ^a   Pandian, K ^a   Kerr, S R ^a   Najarian, J S ^a   Matas, A J ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Cyclosporine levels; Kidney allograft; Rejection

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; PREDNISONE;

ARTICLE; CADAVER KIDNEY; GRAFT SURVIVAL; HUMAN; KIDNEY ALLOGRAFT REJECTION; LIVING DONOR; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REGRESSION ANALYSIS;

ADULT; ANTI-INFLAMMATORY AGENTS; AZATHIOPRINE; CADAVER; CYCLOSPORINE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVING DONORS; LOGISTIC MODELS; MULTIVARIATE ANALYSIS; PREDNISONE; RISK FACTORS; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0030665385     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. MATAS AJ, GILLINGHAM KJ, CHAVERS BM et al. The importance of early cyclosporine levels in pediatric kidney transplantation. Clin Transpl 1996: 10: 482.
2. BASADONNA GP, MATAS AJ, GILLINGHAM KJ et al. Relationship between early vs late acute rejection and onset of chronic rejection in kidney transplantation. Transpl Proc 1993: 25: 910.
3. SUMRANI NB, MILES AM, DASKALAKIS P et al. Intermediate-term outcome of renal retransplants in the cyclosporine era. ASAIO Trans 1993: 39: 47.
4. SHAFFER D, SIMPSON MA, MADRAS PN et al. Kidney transplantation in diabetic patients using cyclosporin. Five-year follow-up. Arch Surg 1995: 130: 283.
5. NANKIVELL BJ, HIBBINS M, CHAPMAN JR. Diagnostic utility of whole blood cyclosporine measurements in renal transplantation using triple therapy. Transplantation 1994: 58: 989.
6. ALMOND PS, MATAS AJ, GILLINGHAM KJ et al. Predictors of chronic rejection in renal transplant recipients. Transpl Proc 1993: 25: 936.
7. MATAS AJ, GILLINGHAM KJ, PAYNE WD, NAJARIAN JS. The impact of an acute rejection episode on long-term renal allograft survival (t1/2). Transplantation 1994: 57: 857.
8. ZINDHOLM A, OHLMAN S, ALBRECHTSEN D, TUFVESON G, PERSSON H. The impact of acute rejection episodes on long-term graft function and outcome in 1347 primary renal transplants treated by 3 cyclosporine regimens. Transplantation 1992: 56: 307.
9. GREVEL J, NAPOLI KL, WELSH MS, ATKINSON NE, KAHAN BD. Prediction of acute graft rejection in renal transplantation: the utility of cyclosporine blood concentrations. Pharmaceutical Res 1991: 8: 278.
10. DAWIDSON I, AR'RAJAB A, LU C, MELONE D. Cyclosporine blood levels predict the likelihood of rejection and toxicity after simultaneous pancreas - kidney transplantation. Transpl Proc 1995: 27: 1324.
11. MEYER MM, MUNAR M, UDEAJA J, BENNETT W. Efficacy of under-the-curve cyclosporine monitoring in renal transplantation. J Am Soc Nephrol 1993: 4: 1306.
12. SCHROEDER TJ, SRIDHAR N, PASCE AJ, ALEXANDER JW, FIRST MR. Clinical correlations of cyclosporine-specific and nonspecific assays in stable renal transplants, acute rejection, cyclosporine nephrotoxicity. Ther Drug Monit 1993: 5: 190.
13. FRYER JP, MATAS AJ. How to identify the best candidates for kidney transplantation. J Crit Illness 1994: 9: 362.
14. FREY DJ, MATAS AJ, GILLINGHAM KJ et al. Sequential therapy - a prospective randomized trial of MALG versus OKT3 for prophylactic immunosuppression in cadaver renal allograft recipients. Transplantation 1992: 54: 50.
15. KNIGHT RJ, KERMAN RH, WELCH M et al. Chronic rejection in primary renal allograft recipients under cyclosporine-prednisone immunosuppress!ve therapy. Transplantation 1991: 51: 355.
16. NICOL D, MACDONALD AS, LAWEN J, BELITSKY P. Early prediction of renal allograft loss beyond one year. Transpl Int 1993: 6: 153.
17. TANABE K, NOVICK AC, STREEM S, HODGE E. Long-term renal function in cyclosporine-treated renal allograft recipients. Urology 1995: 46: 321.
18. STILLER C, KEOWN P. Failure of 125K-tracer selective monoclonal antibody levels on a whole blood matrix to predict rejection or nephrotoxic episodes in renal transplant patients under antilymphocyte globulin and prednisone therapy. Transpl Proc 1990: 22: 1253.
19. MYERS BD, NEWTON L, OYER P. The case against the indefinite use of cyclosporine. Transpl Proc 1991: 23: 41.
20. GREENBERG A, EGEL JW, THOMPSON ME et al. Early and late forms of cyclosporine nephrotoxicity: studies in cardiac transplant recipients. Am J Kidney Dis 1987: 9: 12.
21. GREENBERG A, THOMPSON ME, GRIFFITH BJ et al. Cyclosporine nephrotoxicity in cardiac allograft patients - a seven-year follow-up. Transplantation 1990: 50: 589.
22. HAKIM M, WALLWORK J, ENGLISH T. Cyclosporine A in cardiac transplantation: medium-term results in 62 patients. Ann Thorac Surg 1988: 46: 495.
23. LEWIS RM, VAN Buren CT, RADOVANCEVIC B et al. Impact of long-term cyclosporine immunosuppressive therapy on native kidneys versus renal allografts: serial renal function in heart and kidney transplant recipients. J Heart Lung Transpl 1993: 10: 63.
24. O'GRADY JG, FORBES A, ROLLES K et al. An analysis of cyclosporine efficacy and toxicity after liver transplantation. Transplantation 1988: 45: 575.
25. GONWA TA, MORRIS CA, GOLDSTEIN RM et al. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome - experience in 300 patients. Transplantation 1991: 51: 428.
26. AYERS R, ISMAIL T, ANGRISANI L et al. Long-term renal function in liver transplantation. Transpl Proc 1991: 23: 1469.
27. SOMMERAUER JF, HOWARD J, GRANT D. Renal function following liver transplantation in children. Transpl Proc 1991: 23: 1466.
28. STILLER CR, OPELZ G. Should cyclosporine be continued indefinitely? Transpl Proc 1991: 23: 36.
29. MERION RM, WHITE DJG, THIRU S et al. Cyclosporine: five years' experience in cadaveric renal transplantation. N Engl J Med 1984: 310: 148.
30. WILCZEK H, BOHMAN S-O, KLINTMALM G, GROTH CG. Five-year serial renal graft biopsy study in cyclosporine-treated patients. Transpl Proc 1988: 20: 812.
31. LEWIS RM, VANBUREN CT, KERMAN RH et al. A review of long-term cyclosporine use in renal transplantation. Clin Transpl 1990: 4: 313.
32. BEN-MAIMON CS, BURKE JF, BESARAB A et al. Evidence against chronic progressive cyclosporine nephrotoxicity. Transpl Proc 1991: 23: 1260.
33. MONACO AP, SAHYOUN AI, MADRAS PN et al. Cyclosporine in multidrug therapy in living-related kidney transplantation. Clin Transpl 1990: 4: 347.
34. KLARE B, STROM TM, HAHN H et al. Remarkable long-term prognosis and excellent growth in kidney transplant children under cyclosporine monotherapy. Transpl Proc 1991: 23: 1013.
35. LAND W, SCHNEEGERGER H, SCHLEIBNER S et al. Long-term results in cadaveric renal transplantation under cyclosporine therapy. Transpl Proc 1991: 23: 1244.
36. BURKE JF, PIRSCH JD, RAMOS EL et al. Long-term efficacy and safety of cyclosporine in renal transplant recipients. N Engl J Med 1994: 331: 358.
37. ALMOND PS, GILLINGHAM KJ, SIBLEY R et al. Renal transplant function after ten years of cyclosporine. Transplantation 1992: 53: 316.
38. MATAS AJ, ALMOND PS, Moss A et al. Effect of cyclosporine on renal function in kidney transplant recipients - Twelve-year follow-up. Clin Transpl 1995: 9: 450.
39. ALMOND PS, MATAS AJ, GILLINGHAM KJ et al. Pediatric renal transplants - results with sequential immunosuppression. Transplantation 1992: 53: 46.
40. ALMOND PS, MATAS AJ, GILLINGHAM KJ et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993: 55: 752.
41. KHAULI RB, WILSON JM, BAKER SP, VALLIERE SA, LOVEWELL TD, STOFF JS. Triple therapy in cadaveric renal transplantation: role of induction cyclosporine and targeted levels to avoid rejection. J Urol 1995: 153: 1805.
42. MCCAULEY J, VAN Thiel DH, STARZL TE, PUSCHETT JB. Acute and chronic renal failure in liver transplantation. Ncphron 1990: 55: 121.